Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Syringes for subcutaneous peptide injection
Syringe volume, needle gauge, and length each affect subcutaneous delivery. Here is what GLP-1 prescribing information and CDC injection safety guidance say.
Is tesamorelin banned in sport? WADA status
Tesamorelin is a GHRH analogue prohibited under WADA S2 in and out of competition. Here is what that means and why the TUE picture is unusual.
What is tesamorelin?
Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy. Plain-English guide to its mechanism, one approved indication, and what the Phase 3 trials found.
Tirzepatide dosing: what the trials used
A trial-by-trial map of the dose escalation schedules used across the SURPASS and SURMOUNT programmes, with what each schedule produced at the primary endpoint.
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.
SURMOUNT-OSA post-hoc: who benefits most
SURMOUNT-OSA post-hoc (Sleep, 2026): more-symptomatic patients saw larger subjective gains; objective AHI and weight changes were consistent across subgroups.
Tesamorelin: from discovery to FDA approval
How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.
How Tesamorelin works: the mechanism
Tesamorelin binds GHRH receptors in the pituitary, triggers GH pulses, and raises IGF-1. Plain-English guide to the mechanism.
Tesamorelin side effects and safety data
The FDA label and phase-3 trials list injection site reactions, arthralgia, edema, and a threefold rise in new-onset dysglycemia. Here is what the data show.
Semaglutide around knee replacement surgery
A pilot RCT sets out a 48-week semaglutide protocol around total knee replacement in obese patients. Here is what the paper covers and what remains unanswered.
NITs in MASH: disease-activity vs response
A 2026 letter argues non-invasive liver tests after semaglutide reflect disease activity, not validated response. Here is what that means for MASH trial design.
Semax and WADA: Is It Prohibited in Sport?
Semax is not explicitly named on the WADA Prohibited List, but S2 catch-all language creates genuine ambiguity. Here is what athletes need to know.